ArticleTuberculosis and respiratory diseases2017
Frequency and Type of Disputed
Article in Tuberculosis and respiratory diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical utility of targeted next-generation sequencing for rapid detection, species differentiation, drug resistance profiling, and prognostic evaluation inFrontiers in cellular and infection microbiology · 2026Article
- Phenotypic drug susceptibility characterization and clinical outcomes of tuberculosis strains with A-probe mutation by GeneXpert MTB/RIF.BMC infectious diseases · 2023Article
- Performance Evaluation of the BACTEC MGIT 960 System for Rifampin Drug-Susceptibility Testing of Mycobacterium tuberculosis Using the Current WHO Critical Concentration.Journal of clinical microbiology · 2023Article
- Novel and reported compensatory mutations inFrontiers in microbiology · 2023Article
- Head-to-Head Comparison between Xpert MTB/RIF Assay and Real-Time Polymerase Chain Reaction Assay Using Bronchial Washing Specimens for Tuberculosis Diagnosis.Tuberculosis and respiratory diseases · 2022Article
- Detection ofInfection and drug resistance · 2022Article
- Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.BMC infectious diseases · 2021Article
- DisputedAntimicrobial agents and chemotherapy · 2021Article
- Low-Level Rifampin Resistance andJournal of clinical microbiology · 2021Article
- Whole Genome Sequencing of Drug Resistant and Drug SusceptibleFrontiers in microbiology · 2021Article
- Diagnostic Evaluation of Non-Interpretable Results Associated with rpoB Gene in Genotype MTBDRplus Ver 2.0.Tuberculosis and respiratory diseases · 2020Article
- 16S and 23S rRNA Gene Mutation Independent Multidrug Resistance of Non-Tuberculous Mycobacteria Isolated from South Korean Soil.Microorganisms · 2020Article
- Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact.The Journal of antimicrobial chemotherapy · 2020Article
- Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic.BMC microbiology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA disputed
methodsBetween August 2009 and December 2015, 130 patients exhibited RIF resistance on the MTBDR
resultsAmong our cases, disputed
conclusionDisputed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.